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Exploring the Cost Effectiveness of Shared
Decision Making for Choosing between
Disease-Modifying Drugs for Relapsing-
Remitting Multiple Sclerosis in the
Netherlands: A State Transition Model
Ingrid E. H. Kremer , Mickael Hiligsmann, Josh Carlson,
Marita Zimmermann , Peter J. Jongen, Silvia M. A. A. Evers,
Svenja Petersohn, Xavier G. L. V. Pouwels , and Nick Bansback
Background. Up to 31% of patients with relapsing-remitting multiple sclerosis (RRMS) discontinue treatment with
disease-modifying drug (DMD) within the first year, and of the patients who do continue, about 40% are nonadher-
ent. Shared decision making may decrease nonadherence and discontinuation rates, but evidence in the context of
RRMS is limited. Shared decision making may, however, come at additional costs. This study aimed to explore the
potential cost-effectiveness of shared decision making for RRMS in comparison with usual care, from a (limited)
societal perspective over a lifetime. Methods. An exploratory economic evaluation was conducted by adapting a pre-
viously developed state transition model that evaluates the cost-effectiveness of a range of DMDs for RRMS in com-
parison with the best supportive care. Three potential effects of shared decision making were explored: 1) a change
in the initial DMD chosen, 2) a decrease in the patient’s discontinuation in using the DMD, and 3) an increase in
adherence to the DMD. One-way and probabilistic sensitivity analyses of a scenario that combined the 3 effects were
conducted. Results. Each effect separately and the 3 effects combined resulted in higher quality-adjusted life years
(QALYs) and costs due to the increased utilization of DMD. A decrease in discontinuation of DMDs influenced the
incremental cost-effectiveness ratio (ICER) most. The combined scenario resulted in an ICER of e17,875 per QALY
gained. The ICER was sensitive to changes in several parameters. Conclusion. This study suggests that shared deci-
sion making for DMDs could potentially be cost-effective, especially if shared decision making would help to
decrease treatment discontinuation. Our results, however, may depend on the assumed effects on treatment choice,
persistence, and adherence, which are actually largely unknown.
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Multiple sclerosis (MS) is a progressive demyelinating
and degenerative disease of the central nervous system,
causing physical and cognitive disabilities and a substan-
tial loss of quality of life.1–3 In the Netherlands, 88 per
100,000 people are diagnosed with MS, and each year
another 5 per 100,000 people will receive the diagnosis.4
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Different courses of MS can be distinguished, the major-
ity of patients (approximately 89%) having the relapsing-
remitting course of MS (RRMS) at onset.4 RRMS is
characterized by relapses (i.e., the occurrence of new
symptoms or exacerbations of existing symptoms), fol-
lowed by remissions, in which the symptoms recover
completely or incompletely, and stable periods.5,6 RRMS
patients could transition to a secondary progressive MS
(SPMS) course, characterized by a transition from
relapses and remissions to a gradual continuous worsen-
ing of symptoms.5,6 In the Netherlands, cost of MS
summed up to e204.2 million (0.21% of total health care
expenditures) in 2017, consisting of 46% of hospital and
specialist care and 35% of drug treatment.7
Currently, a large number of disease-modifying drugs
(DMDs) are available to reduce the number and severity
of relapses in patients with RRMS.8,9 By reducing the
number and severity of relapses, DMDs also delay the
accumulation of disabilities. Patients with RRMS most
often have several options in the treatment with DMDs,
including the choice to refrain from DMD use. The use
of DMDs can be burdensome for patients due to side
effects and administration regimens; these characteristics
differ between DMDs.
Decision making about treatment for RRMS is there-
fore difficult, and the patient should be involved10 for sev-
eral reasons. First, more efficacious DMDs are associated
with a higher risk of severe or life-threatening adverse
events, resulting in these DMDs typically being indicated
for patients with high disease activity.11 Moreover,
patients experience the burden of administration and
common side effects differently, which puts a different
value on DMDs with certain attributes.12 Second, health
care providers making a treatment decision without con-
sulting the patient often make inaccurate assessments of
the patient’s preferences for treatment options, instead
basing assessment on personal preferences and experience.13
Third, persistence with and adherence to treatment regi-
mens are suboptimal among many patients.14–17 Treatment
persistence refers to ‘‘the length of time between initiation
and the last dose, which immediately precedes discontinua-
tion,’’ with discontinuation referring to the patients stop-
ping the medication.18 With treatment adherence, we refer
to the ‘‘implementation’’ component according to the tax-
onomy by Vrijens et al.18: ‘‘the extent to which a patient’s
actual dosing corresponds to the prescribed dosing regimen,
from initiation until the last dose.’’19 Real-world studies in
RRMS show that discontinuation rates in the first year
after DMD treatment initiation range between 10% and
31%.15–17 Of the people who do persist, only 60% of
patients taking injectable or orally administered DMDs
were reported to have optimal adherence.14
Shared decision making is an approach that can help
explicitly to integrate informed patient’s preferences for
treatment options into clinical decisions.20 Health care
professionals enable the patient to develop informed pre-
ferences for treatment options by sharing information.
In turn, the patient shares his or her preferences with the
health care provider. Consecutively, the patient and
health care professional discuss the best matching treat-
ment options, considering the patient’s preferences and
the best available evidence, to make a treatment decision
together.20 Shared decision making is often supported by
patient decision aids, which inform patients about their
options and help them to understand and express their
preferences.21 Patient decision aids have been shown to
facilitate shared decision making21 and could improve
treatment adherence.22
The implementation of shared decision making with or
without a patient decision aid can also have implications
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for resources. Trenaman et al.23 distinguish 3 categories
for how resources could be affected through the use of a
patient decision aid, potentially increasing or decreasing
costs: 1) delivery of the patient decision aid and its effect
on consultation time, 2) short-term costs because patients
may opt more often for more or less expensive options,
or 3) long-term costs because of a postponed intervention
or changes in persistence and adherence. For example,
implementation of shared decision making with or with-
out patient decision aids could increase consultation time
and thus increase costs.21 Furthermore, cost reductions in
the short term have been reported for one-off interven-
tions because patients chose less invasive and less costly
interventions.24,25 In addition, patient education and value
elicitation could support patients in developing a more per-
sistent and adherent attitude toward taking a particular
medication. As a result, health outcomes would improve
and utilization of health care, and consequently costs,
would decrease.26 The consequences for costs may depend,
however, on the treatment decision and the context.23
While there is less evidence on the consequences of shared
decision making and patient decision aids regarding persis-
tence, adherence, health outcomes, and costs for chronic
diseases requiring long-term treatment,23 various efforts
are under way to create training and tools for MS.
An investment in shared decision making has an oppor-
tunity cost, diverting funds used for other aspects of the
health care system, including the budgets used to pay for
drugs. It is therefore important to understand the cost-
effectiveness of shared decision making, similar to how
decision makers assess the cost-effectiveness of drugs for
reimbursement decisions.27 Accordingly, this study aim-
ed to evaluate the potential lifetime cost-effectiveness of
shared decision making with regard to DMDs for
RRMS in comparison with usual care from a societal
perspective. The study had an exploratory nature to
determine the headroom for implementation of shared
decision making for DMDs for RRMS. Therefore, we
also estimated the maximum costs at which shared deci-
sion making remains cost-effective. Although evidence
for the effects of shared decision making is limited, the
results of this early economic evaluations could inform
decision makers and clinicians about the potential value
of implementing shared decision making in clinical prac-
tice before wide implementation of the approach is rea-
lized. By explicitly modeling the different consequences
of shared decision making (i.e., the costs of delivery of
shared decision making, treatment choice, persistence
and adherence) on relapses, quality-adjusted life years
(QALYs), and costs, this study also aimed to reveal
which effects drive the cost-effectiveness. Results could
underline the need to develop effective interventions for
implementing shared decision making (e.g., patient deci-
sion aids) and to help in designing future trial-based and
model-based economic evaluations of shared decision
making and other interventions focused on improving
persistence and adherence during long-term treatment.
Methods
We adapted a state transition model developed by the
Institute for Clinical and Economic Review, an indepen-
dent and nonpartisan research institute, in the United
States.28 The model evaluated the cost-effectiveness of
a range of DMDs for MS.28 The model structure and
inputs, based on various other models,29–35 have previ-
ously been validated through rounds of public comments,
cross-validation with other models, and sensitivity analy-
ses.28 We modified the model to assess the cost-effectiveness
of implementing shared decision making regarding DMDs
choice and estimated the potential societal costs, QALYs,
and incremental cost-effectiveness using a Dutch per-
spective and following clinical practice and guidelines for
economic evaluations in health care.36 For reporting, we
followed the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS).37
Population
The modeled population were adults with RRMS with-
out prior experience with DMDs in the Netherlands.
These patients had a mean age of RRMS onset of 37
years.38,39 Within this population, 29% were male.38,39
Intervention and Comparator
Implementation of shared decision making in the inter-
vention group was compared with usual care in the con-
trol group. In the intervention group, the health care
professional applies the principles of shared decision
making with the patient during the decision making pro-
cess about DMDs. Patient decision aids are commonly
used during or between 2 consultations to educate patients
about their treatment options and to help clarify personal
values regarding the treatment options.21 During a (follow-
up) consultation, the patient and health care professional
discuss the treatment options and the patient’s preferences
to make an informed and shared decision on treatment.20
In the control group, we assume that usual care decisions
are mostly made in accordance with the health care profes-
sional’s judgment of what fits best with the patient’s needs,
with little attempt to determine or acknowledge what the
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patient’s preferences might be with regard to the decision.
In both groups, patients would be prescribed a treatment
with a DMD or no active treatment (best supportive care).
Model Structure
To model the disease course of RRMS and the risk for
progression to SPMS, 20 health states (i.e., 10 health
states for RRMS and 9 health states for SPMS and
death) (Figure 1), defined by the Expanded Disability
Status Scale (EDSS), were included according to the
model described by Zimmermann et al.40 The EDSS, admi-
nistered by a physician, measures neurological impairment
in patients with MS on an ordinal scale from 0 (no impair-
ment) to 10 (death), defined by the degree of impairment
in functional systems, such as pyramidal, cerebellar, sen-
sory, and visual functions, and the degree of ambulatory
problems.41 Patients with RRMS could enter the model
in health states with an EDSS score between 0 and 9.
During a cycle of 12 months, patients could improve or
worsen in RRMS health states, remain stable, or prog-
ress to SPMS. The transition probabilities were esti-
mated based on natural history.33 The effectiveness of
each DMD is modeled through applying a relative risk
for each DMD to the transition probabilities.40 In the
SPMS health states, patients could progress to a higher
EDSS state or remain in the same health state (i.e.,
patients could not improve). Patients could experience a
relapse or die in each health state. Patients transitioning
to SPMS were assumed to continue treatment based on
current clinical opinion.40 If patients discontinued their
first DMD, they could switch to another DMD or to
best supportive care. After discontinuation of the second
DMD, patients were assumed to be switching to best
supportive care. The model takes a lifetime horizon: the
effects of shared decision making on costs and QALYs
are simulated until a patient dies or reaches the age of
100. A limited societal perspective was taken, in which
health care costs and costs outside the health care sector
(i.e., productivity losses related to MS, informal care,
out-of-pocket or copayments for patients for equipment,
aids and modifications, and community services, such as
home help, transportation, or personal assistance) were
included. A discount rate of 1.5% for effects and of
4.0% for costs was applied in accordance with the Dutch
guideline for economic evaluations in health care.36
Table 1 presents key assumptions made in the model.
Intervention Effects
Three effects of shared decision making were assumed
and modeled (Figure 2 and further specified in the sup-
plementary material): 1) shared decision making changes
the DMD mix chosen, 2) shared decision making
increases the proportion of optimally adherent patients,
and 3) shared decision making increases persistence with
the chosen treatment. Key assumptions for modeling
shared decision making in comparison with usual care
Figure 1 Health state transition model structure for multiple sclerosis course, adapted from Zimmermann et al.40 Patients with
RRMS enter the model in any health states defined by neurologic impairment measured with the EDSS. Higher EDSS scores
indicate worse neurologic impairment. During a cycle, patients can stay in their current health state or transition to a consecutive
lower or higher health state. Patients can also transition to SPMS or die. In any health state, patients can experience a relapse.
EDSS, Expanded Disability Status Scale; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple
sclerosis.
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are presented in Table 1. Effect 1 was based on the fact
that patients’ preferences are elicited and included in the
treatment choice during a shared decision making pro-
cess, and these preferences might differ from physicians’
preferences.13 The proportions of patients initiating a
specific DMD treatment or opting for best supportive
care were therefore assumed to differ between the
groups, also following studies for other health deci-
sions.24,25,42,43 The treatment initiation and treatment
sequencing (i.e., the categorization of DMDs in first-line
treatments for mild to moderate RRMS and in second-
line treatments for highly active RRMS or RRMS not
responding to first-line treatment) was informed by cur-
rent clinical practice in the Netherlands, based on expert
opinions and recommendations provided by the Dutch
Healthcare Institute,11 in the absence of formal up-to-
date clinical guidelines. Effects 2 and 3 were based on
the theory by Stalmeier26 that patients develop a more
pronounced attitude toward taking the medication con-
tinuously and accurately. Patients are expected to be bet-
ter informed and consequently have more accurate
expectations about the effects and treatment burden of
the chosen treatment option.26 Consequently, a better
match is made between the patient’s preferences and the
treatment attributes. Patients on DMD treatment can be
either optimally adherent or nonadherent over time.
Nonadherent patients were assumed to not experience
the full benefits of the DMDs and have a 42% higher
risk of relapses overall14 and a 7.5% higher risk of severe
relapses specifically.44 A weighted average of the out-
comes was calculated.
Usual care profile. A profile for the usual care group
was defined, and these parameters were kept constant for
usual care in all further analyses. The usual care profile is
presented in Table 2.
Treatment choice. Due to a lack of published data
about the proportion of newly diagnosed patients choos-
ing to start DMD treatment or best supportive care, rates
were based on expert opinion, informed by data describ-
ing current use of each DMD by patients from the Drug
Information System of the National Health Care Institute
in the Netherlands.45
Discontinuation. Discontinuation rates of drug thera-
pies reported in controlled phase II or III trials are most
likely the optimal persistence rates among patients using
the DMD but do not reflect real-world persistence as
these are often lower.15–17,46 Therefore, discontinuation
rates were based on real-world data, defined as more
than 90 days’ interruption in treatment with the chosen
DMD measured using pharmacy records.15–17 No data
were available for ocrelizumab and alemtuzumab. Dis-
continuation rates were therefore determined based on
the rate of natalizumab, proportionately according to
differences found in trial discontinuation rates between
Table 1 Key Assumptions of the Health State Transition Model for MS Course by the Institute for Clinical and Economic
Review and Key Assumptions for the Adapted Health State Transition Model Comparing Shared Decision Making with Usual
Care
Assumptions of the health state transition model for MS course by Institute for Clinical and Economic Review
28,40
 Mortality risk within each health state was the same for RRMS and SPMS.
 Patients progressing to SPMS continued treatment with DMD.
 Patients discontinue treatment if they progressed to a health state EDSS .6.
 The treatment effects of a DMD were equal for the first choice and the second choice.
 After discontinuation of second DMD, patients switch to best supportive care.
 No vial sharing was included.
Additional assumptions of the health state transition model comparing shared decision making with usual care
 Distribution of EDSS state of Dutch patients entering the model was equal to the original model.
 In usual care, decisions are mostly made in accordance with the health care professional’s judgment with little involvement
of the patient’s preferences in the decision.
 Shared decision making affects initial treatment choice, DMD discontinuation, and DMD adherence.
 Effects of shared decision making on adherence and persistence remain stable over time.
 Nonadherent patients experience limited effects of the DMD.
 Discontinuation rates of the second DMD were equal to the discontinuation rate of the first DMD.
 Patients choosing best supportive care as initial treatment choice remained on best supportive care.
DMDs, disease-modifying drugs; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis;
SPMS, secondary progressive multiple sclerosis.
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ocrelizumab, alemtuzumab, and natalizumab. After
discontinuation of the first DMD, patients could switch
to another treatment or to best supportive care. Experts
concluded that about 95% of patients who discontinued
their first treatment would switch to another DMD
treatment. From pivotal studies, it was estimated that
79%47–57 of patients discontinue due to side effects and
21%48–53,56 of patients discontinue due to a perceived
lack of efficacy. Patients stopping first-line treatment
due to side effects were assumed to switch to another
first-line DMD. Patients stopping first-line treatment
due to a perceived lack of efficacy were assumed to
Figure 2 Health state transition model structure for the cost-effectiveness of shared decision making in multiple sclerosis.
Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) receive either usual care or shared decision making to
make a decision regarding treatment with disease-modifying drug. Three effects of shared decision making are modeled: 1) a
change in initial treatment choice, 2) a decrease in discontinuation rate (persistence), and 3) an increase in the proportion of
adherent patients. These effects are marked in the figure with a black circle and the corresponding number. If patients choose a
drug treatment, they are either adherent (i.e., having more than 80% of days covered) or nonadherent. Nonadherent patients
were assumed to have higher risks of experiencing (severe) relapses. For adherent and nonadherent patients, a simplified picture
of the health state transition model for multiple sclerosis (MS) course is presented. The full model structure is provided in Figure
1. In short, patients enter the model in any of 10 RRMS-related health states based on the Expanded Disability Status Scale
(EDSS). While the figure presents EDSS states A and B, these should be interpreted as the different EDSS levels (i.e., EDSS
levels 0 through 10). During each 12-month cycle, the patients’ disability status could worsen, improve, or remain stable.
Moreover, patients could progress to secondary progressive MS (SPMS). Patients could experience a relapse or die in any health
state. If patients discontinue their initial treatment, they are assumed to switch to another active treatment or to best supportive
care according to a predetermined probability. If patients discontinue their second treatment, they are assumed to be switching
to best supportive care. DMD, disease-modifying drug.
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switch to a more effective (second-line) DMD (i.e., nata-
lizumab, fingolimod, alemtuzumab, or ocrelizumab). If
second-line DMD users discontinued treatment, they
were assumed to switch to another second-line DMD
(supplementary material).
Adherence. The proportion of adherent patients (patients
with more than 80% of days covered) was measured
using claim data and was set to 58.9% for self-injectable
and oral DMDs in the usual care group.14 Since admin-
istration of alemtuzumab, ocrelizumab, and natalizu-
mab takes place in the hospital, is less frequent, and is
prescribed to patients with more active disease, 100% of
patients taking these DMDs were assumed to have opti-
mal adherence.
Shared decision making profile. The profile for shared
decision making according to the 3 assumed effects was
determined relative to the profile of usual care. The pro-
file is specified in Table 2.
Effect 1: Treatment choice. Including the patient’s preferences
in treatment decisions may change the choice.24,25,42,43
No evidence is yet available about how shared decision
making could influence the treatment choice for MS.
Based on stated preference studies, we constructed a
possible profile regarding the initial treatment choice for
the patients making a shared decision with their health
care professional. Stated preference studies report that
patients value the effects of the DMD most, more than
safety, ease of use, and side effects.12,58 Moreover, oral
medications have been reported to be preferred in com-
parison with injectable medications.59–62 Because first-
line medications have similar effects and safety profiles,
the profile specified that fewer patients start self-
injectable first-line DMDs. Stated preference research
further suggests that MS patients are less risk averse
than neurologists63 and are willing to accept even higher
risks than are currently associated with DMDs.63,64
Therefore, this profile specified that a slightly larger pro-
portion of patients with relatively high disease activity at
first treatment initiation would initiate a second-line treat-
ment if the decision were shared between the patient and
the health care professional. The proportion of patients
starting each treatment option is specified in Table 2. A
variation on the scenario was conducted as well in sensitiv-
ity analyses (i.e., assuming the change in treatment would
be 50% smaller, resulting in a more conservative profile).
Effect 2: Discontinuation. Patients in the intervention
group were assumed to be more persistent in using the
chosen DMD because they are better informed about its
efficacy and side effects, have been involved in the
treatment decision, and there is a better match between
the patient’s preferences and the chosen treatment.26 A
relative decrease in the discontinuation rate of 50% was
applied for the group receiving shared decision making
compared with the group receiving usual care. This
resulted in an averaged absolute decrease in discontinua-
tion rate of 11.1% over the different DMDs, which was
in line with a previous economic evaluation regarding a
decision aid for shared decision making in osteoporosis
assuming a 10% decrease in the discontinuation after
shared decision making.42 The relative decrease in the
discontinuation rate was varied to 25% and 75% in sen-
sitivity analyses.
Effect 3: Adherence. In previous studies on patient
decision aids for other shared health care decisions,
improvement rates in the proportion of adherent patients
varied between 0% and 50%.42,43 Because no data are
available for MS, a conservative assumption was made
regarding improvement for the proportion of adherent
patients (i.e., a 5% improvement in comparison with usual
care). This rate was increased in 1-way sensitivity analyses
to 10% and up to 100% of patients being adherent.
Model inputs
Effect estimates. Estimates of effectiveness of DMDs
in reducing relapses, slowing down disease progression,
and transition probabilities between health states were in
accordance with the model published by Zimmermann
et al.40 based on a Bayesian network meta-analysis using
33 clinical trials (supplementary material). Age- and
gender-specific background mortality rates were derived
from Statistics Netherlands,65 which were adjusted for
MS-specific mortality based on the EDSS score.66
Utilities. Utilities and disutilities associated with health
states, relapses, and adverse events were in accordance with
the original model (supplementary material).28,40
Costs. Costs were expressed in euros (1 euro = 1.16
US dollars: August 2018). All costs were, where neces-
sary, inflated using the Consumer Price Index for August
2018.67
DMD costs. Costs of DMDs (supplementary mate-
rial) were determined using the Pharmacy Purchase Price
included in the database of the National Health Care
Institute in the Netherlands (www.medicijnkosten.nl). A
e14 dispensing fee for pharmacists was added for each
first prescription and e7 for each subsequent prescrip-
tion.68 Administration costs for alemtuzumab, natalizu-
mab, and ocrelizumab were included since these DMDs
are administered through intravenous infusion in the
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hospital. In the Netherlands, alemtuzumab requires hospitali-
zation of patients during the treatment period, while
natalizumab and ocrelizumab only require outpatient
day treatment. Self-injectable or orally administrated
DMDs do not incur additional administration costs.
Costs related to monitoring recommended in the pack-
age inserts were included per DMD. Pretreatment moni-
toring costs were included in the first year of treatment.
Any monitoring required after discontinuation, includ-
ing an extra specialist visit, was added as well.40 Health
care utilization unit costs were determined in accordance
with the Dutch manual for economic evaluations based on
reference prices established by the National Healthcare
Institute69 or based on tariffs from the Dutch Healthcare
Authority70 (see the supplementary material).
Adverse events costs. The costs of adverse events are
covered by the Dutch ‘‘diagnosis-related-group’’ (DRG)
system. However, these DRG rates are not publicly avail-
able. The costs of adverse events contribute only margin-
ally to the total costs.40 Therefore, we first calculated the
adverse events costs as proportion of the health care costs
in the original model40 and applied the same percentage
to calculate the adverse events costs as a proportion of
the health care costs for the Dutch context in our model.
Health state costs. Health state costs for each EDSS
health state were calculated by interpolating the EDSS
costs reported by Uitdehaag et al.71 (supplementary
material). From a societal perspective, health care costs
(i.e., inpatient care, day admission, consultations, tests,
and medications other than DMDs), community ser-
vices, investments in equipment, aids or modifications,
informal care, and productivity losses were included. For
productivity losses, only short-term absence costs were
included according to the friction cost method required
by the Dutch economic evaluation guideline.72 A sensi-
tivity analysis was conducted in which productivity
losses also included the costs of long-term absence, dis-
ability, and early retirement, according to the human
capital approach.73 Relapse costs were also derived from
Uitdehaag et al.71
Costs of shared decision making. Estimating the costs
of shared decision making is complicated due to the het-
erogeneous nature of how shared decision making may
be implemented in clinical practice. It could involve
training of health care providers, development (including
[pilot] research into the effects), distribution and imple-
mentation of patient decision aids that could have many
forms (paper-based or app-based, online, or computer-
based patient decision aids), and additional health care
provider (MS nurse and/or neurologist) time caused by
additional consultations or increased consultation time.23
Although patient decision aids have been shown to
Table 2 Specification of the Profiles of Usual Care and Shared Decision Making per Treatment Based on the 3 Assumed Effects
of Shared Decision Makinga
Effect 1, % Effect 2, % Effect 3, %
Treatment Initiation Discontinuation Rate Proportion Adherent
CAU SDM CAU SDM CAU SDM
Best supportive care 25.0 20.0 NA NA 100.0 100.0
Alemtuzumab 0.2 0.3 10.4 5.2 100.0 100.0
Dimethyl fumarate 33.6 41.3 21.4 10.7 58.9 63.9
Fingolimod 0.0 0.0 10.6 5.3 58.9 63.9
Glatiramer acetate 20 mg (generic) 0.2 0.1 26.7 13.4 58.9 63.9
Glatiramer acetate 20 mg (brand) 10.6 3.5 26.7 13.4 58.9 63.9
Glatiramer acetate 40 mg (brand) 0.2 0.1 21.5 10.8 58.9 63.9
Interferon b-1a 1.0 0.3 26.8 13.4 58.9 63.9
Interferon b-1a 22 mcg 0.5 0.2 27.1 13.6 58.9 63.9
Interferon b-1a 44 mcg 0.5 0.2 30.1 15.1 58.9 63.9
Interferon b-1b 1.0 0.3 25.9 13.0 58.9 63.9
Natalizumab 4.0 6.0 13.0 6.5 100.0 100.0
Ocrelizumab 0.8 1.2 13.1 6.6 100.0 100.0
Peginterferon b-1a 1.0 0.3 26.4 13.2 58.9 63.9
Teriflunomide 14 mg 21.4 26.3 20.8 10.4 58.9 63.9
CAU, care as usual; NA, not applicable; SDM, shared decision making.
aDifferent parameter values for the 3 effects of shared decision making were varied separately in sensitivity analyses. The values presented here
were combined for the main base case scenario.
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extend consultation time with a median of 2.6 minutes,23
there are little data available about the costs of shared
decision making, and no data are available for shared
decision making in MS. Therefore, we assumed a mean
cost per patient of e100, which would cover a scenario of
an increase in consultation time of 50% (e51.77) and any
costs for training of health care providers, development,
and implementation of a patient decision aid up to
e48.23 per patient. Shared decision making is assumed
to be applied each time a treatment choice is made (i.e.,
patients discontinuing their first treatment will choose
their second treatment again via shared decision making).
Analyses
Analyses were conducted in Excel 2016 (Microsoft
Corporation, Redmond, WA). Drug costs, adverse event
costs, other costs within and outside the health care sec-
tor, total societal costs, QALYs, number of relapses, and
life years were calculated separately for shared decision
making and for usual care. This enabled the calculation
of incremental cost effectiveness ratios (ICERs).
The 3 effects of shared decision making were first ana-
lyzed separately in comparison with usual care and were
then assessed in a combined scenario: a 10% decrease in
the discontinuation rate in comparison with usual care, a
5% increase in patients with optimal adherence in com-
parison with the usual care group, and initial treatment
choices as specified in Table 2. Because of the heteroge-
neous nature of shared decision making in terms of con-
sultation time, health care professionals involved, and
supporting tools used, complicating the estimation of the
costs of shared decision making, a threshold analysis was
performed for each effect separately and for the 3 effects
combined to determine the maximum costs of shared
decision making at which the ICER would exceed the
thresholds of e20,000/QALY and e50,000/QALY.74 For
the combined profile of the 3 effects, we conducted fur-
ther 1-way sensitivity analyses to evaluate the influence
of several parameters on the ICER: drug costs (+20%;
–20%), costs of implementing shared decision making
(e0), mean age of RRMS onset (29; 45 years old), pro-
portion male (18%; 40%), patient distribution over
EDSS levels when entering the model (100% in EDDS
level 1; 100% in EDSS level 4; –3.75% in EDSS levels
0–3 and +5% in EDSS levels 4–6), transition proba-
bilities moving between health states (+10%; –10%),
choice of initial DMD (equal distribution over first-line
DMDs only, no best supportive care; equal distribution
over first-line DMDs only, with 20% choosing best
supportive care), choice for secondary DMD after first
discontinuation (switch to second-line DMDs only with
equal distribution; switch from first-line DMDs to first-
line and second-line DMDs with equal distribution), dis-
count rate (3%; 0% for both QALYs and costs), and
the perspective taken (health care perspective, societal
perspective using the human capital approach for
calculating productivity losses). In addition, a proba-
bilistic sensitivity analysis with 10,000 iterations was
conducted for the combined effects, which was pre-
sented in a cost-effectiveness plane. A cost-effectiveness
acceptability curve was constructed to present the
probability that shared decision making would be cost-
effective in comparison with usual care at a range of
willingness-to-pay thresholds. Specifications for distri-
butions of the effects of shared decision making are
included in the supplementary material. Distributions
of other parameters were selected in line with the model
developed earlier.40
Model Validation
Model transparency and internal validity were reviewed
by 2 independent researchers (SP, XGLVP). Evaluation
of internal validity consisted of internal testing and
debugging using null input values—as recommended by
the ISPOR-SMDM Modeling Good Research Practices
Task Force75—for utilities and disutilities, probabilities
of relapses, adverse events costs, discount rates, drug
costs, all costs, and changes in the cohort size. In addi-
tion, cell-by-cell verification of input calculations and
formulas was conducted to identify any errors. Last,
external validity was evaluated by comparing life expec-
tancy predicted by the model for the Dutch population
with published estimates.
Results
Modeling each effect of shared decision making sepa-
rately showed that shared decision making resulted in
higher QALYs and costs (Table 3). The associated ICERs
ranged from e4384 to e315,555 per QALY gained.
Treatment Choice
A change in choice of the type of treatment as specified
in Table 2 resulted in an increase in drug cost of e8288.
Health state costs decreased by e3384, resulting in an
overall cost increase. Overall QALYs increased (0.21
QALYs gained). A more conservative change in treat-
ment choice resulted in similar but slightly smaller
consequences.
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Discontinuation
Total costs increased if discontinuation rates dropped
50% due to a larger proportion of patients being persis-
tent with their treatment choice, resulting in e15,275 in
higher drug costs. On the other hand, patients also experi-
enced more beneficial effects, resulting in 0.23 more
life years, 0.29 less relapses, 0.80 more QALYs, and, con-
sequently, e11,755 less in health state costs. Varying the
relative reduction in discontinuation rate of DMDs from a
50% decrease to a 25% or 75% decrease affected the
ICER slightly, resulting in an ICER of e4384 and e6828
per QALY gained, respectively, for a 50% and 75%
reduction and for shared decision making being the domi-
nant choice if the relative reduction would only be 25%.
Adherence
A change in the proportion of adherent patients of 5%
showed minimal beneficial effects (0.01 QALYs gained,
0.03 fewer relapses). This resulted in a major increase in
the ICER to e315,555. Varying the adherence from 10%
to 100% did not affect the ICER substantially.
Combined Effects
Combination of all 3 effects resulted in an ICER of
e17,875 per QALY gained. The increase in total costs of
e20,009 was driven by increased drug costs of e36,678.
The beneficial effects translated into a QALY gain of
1.12, reduction of relapses of 0.49, life years gained of
0.31, and a reduction in health state costs of e16,666.
More detailed results for all effects separately and the
combined effects are included in the supplementary
material.
Sensitivity Analyses
Sensitivity analyses of the separate effects showed that, if
shared decision making was assumed to decrease the rela-
tive reduction in discontinuation rate by 25%, the total
costs for the intervention group would be e807 less in
comparison with the control group due to a decrease in
health state costs of e4994 and an increase of drug costs
of e4189, resulting in shared decision making being the
dominant choice. In all scenarios, increased drug use was
the main cost driver, while other costs within and outside
the health care sector decreased (supplementary material).
Results of 1-way sensitivity analyses of the combined
effects as defined in Table 2 are presented in Table 4 (fur-
ther detailed in the supplementary material). The ICER
was highly sensitive to change in the relative risk of each
DMD option for EDSS progression. Furthermore, the
substantial influence of drug costs on the ICER was con-
firmed: a 20% increase and decrease in DMD costs
resulted in ICERs of e24,147 and e11,604 per QALY
gained, respectively. Moreover, the ICER increased to
e25,568 and e29,191 if, respectively, a discount rate of
3% or a health care perspective was applied. A change in
Table 3 Cost-Effectiveness Results from Analyses of the 3 Assumed Potential Effects of Shared Decision Making
Usual Care Shared Decision Making Incremental
Modeled Effect of Shared Decision
Making (Deviation from CAUa) Total Costs QALYs Total Costs QALYs D Costs D QALY ICER
Initial DMD choice Table 2 e397,646 7.67 e402,551 7.88 e4904 0.21 e23,509
250%b e397,646 7.67 e400,181 7.78 e2535 0.10 e24,294
Discontinuation rate 250% e397,646 7.67 e401,163 8.47 e3517 0.80 e4384
225% e397,646 7.67 e396,840 8.00 2e807 0.33 Dominant
275% e397,646 7.67 e407,635 9.13 e9988 1.46 e6828
Proportion of adherent patients +5% e397,646 7.67 e400,878 7.68 e3231 0.01 e315,555
+10% e397,646 7.67 e403,972 7.69 e6325 0.02 e308,843
100% e397,646 7.67 e422,535 7.75 e24,889 0.08 e303,809
Combined effects (base case) a e397,646 7.67 e417,655 8.79 e20,009 1.12 e17,875
CAU, care as usual; DMD, disease-modifying drug; ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years.
aThe 3 effects of shared decision making included in the model are initial treatment choice, discontinuation rate, and adherence. Bolded rows
present the values of parameters included in the combined effect analysis. In usual care, 25% of people choose best supportive care, 5% choose a
DMD indicated for highly active multiple sclerosis (natalizumab/alemtuzumab), and 70% choose one of the first-line DMDs (25% for a first-
generation first-line DMD, 45% for a second generation first-line DMD). Discontinuation rates range between 10% and 31%, depending on the
DMD. The proportion of patients with optimal adherence is 58.9%, except for natalizumab, alemtuzumab, and ocrelizumab, for which
adherence is assumed to be 100%.
bChange in treatment choices was reduced with 50% compared to the change in treatment choice as specified in Table 2.
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mean age of MS onset, the transition probabilities, and
the choice for the initial and secondary treatment after
the first discontinuation also affected costs and QALYs,
resulting in ICERs ranging from e14,812 to e24,147. The
threshold analyses suggest that, in the scenario of com-
bined effects, shared decision making could maximally
cost e23,639 to be cost-effective at a threshold of e50,000
per QALY (Table 5). Figure 3 presents the ICERs for
the 10,000 iterations of the probabilistic analysis in a
cost-effectiveness plane for the combined effects. The
probability of shared decision making being cost-






Making v. Usual Care
Parameter Total Cost QALYs Total Cost QALYs D Costs D QALY ICER
Base case (combined effects of shared
decision making)
e397,646 7.67 e417,655 8.79 e20,009 1.12 e17,875
Drug costs+20% e406,905 7.67 e433,934 8.79 e27,029 1.12 e24,147
Drug costs 220% e388,387 7.67 e401,376 8.79 e12,989 1.12 e11,604
Relative risk for EDSS progression per
DMD: lower rangeb
e384,371 8.58 e398,972 10.50 e14,601 1.91 e7,640
Relative risk for EDSS progression per
DMD: upper rangeb
e413,913 6.53 e438,023 6.88 e24,110 0.34 e70,084
Costs of shared decision making: e0 e397,646 7.67 e417,502 8.79 e19,856 1.12 e17,739
Discount rate: 0% e811,208 8.45 e839,286 9.98 e28,078 1.53 e18,307
Discount rate: 3% e465,321 6.98 e486,766 7.82 e21,445 0.84 e25,568
Health care perspective e203,427 7.67 e236,101 8.79 e32,675 1.12 e29,191
Human capital approach e728,727 7.67 e744,564 8.79 e15,837 1.12 e14,149
Age at onset RRMS: 29 e447,395 7.17 e465,567 8.40 e18,173 1.23 e14,812
Age at onset RRMS: 45 e342,864 7.93 e364,618 8.91 e21,753 0.98 e22,285
Proportion male: 40% e395,111 7.69 e415,203 8.81 e20,093 1.11 e18,046
Proportion male: 18% e400,287 7.65 e420,208 8.78 e19,920 1.13 e17,700
EDSS level at start: 100% EDSS level 1 e370,333 9.29 e392,278 10.53 e21,946 1.24 e17,709
EDSS level at start: 100% EDSS level 4 e434,088 5.58 e451,517 6.54 e17,429 0.96 e18,132
EDSS level at start: equal distributions
across health states
e393,989 6.59 e412,906 7.59 e18,917 1.00 e18,915
Choice initial DMD: only first-line DMD,
equal proportions, no best supportive
care
e397,646 7.67 e423,174 8.80 e25,527 1.12 e22,722
Choice initial DMD: only first-line DMD,
25% best supportive care
e406,905 7.67 e433,934 8.79 e27,029 1.12 e24,147
Choice second DMD: only second-line
DMT with equal distributions
e399,151 8.17 e421,325 9.51 e22,174 1.34 e16,530
Choice second DMD: equal distributions
across first line and second line
e396,515 7.83 e416,479 9.03 e19,964 1.20 e16,634
Transition probabilities:+10% e403,414 7.21 e422,280 8.33 e18,866 1.13 e16,721
Transition probabilities: 210% e391,241 8.20 e412,523 9.30 e21,283 1.11 e19,246
DMD, disease-modifying drug; EDSS, Expanded Disability Status Scale; ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted
life years; RR, relative risk.
aAs specified for usual care and shared decision making in Table 2.
bRange per DMD is specified in the supplementary material.
Table 5 Threshold Analyses for Maximum Costs of Shared
Decision Making to Be Cost-Effective
Threshold
Effect Size of Effect
a
e20,000 e50,000
Initial treatment choice Table 2 e2340.89 e3,428.17
Discontinuation rate 250% e8,440.43 e24,463.51
Proportion adherent +5% e22,101.69 e21,878.21
Combined effects e1,656.86 e23,638.95
aDeviation from usual care.
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Figure 3 Incremental cost-effectiveness plane for the combined effects for initial disease-modifying drug choice, persistence, and
adherence of shared decision making v. usual care. QALYs, quality-adjusted life years; WTP, willingness-to-pay threshold.
Figure 4 Cost-effectiveness acceptability curve for the combined effects for initial disease-modifying drug choice, persistence, and
adherence of shared decision making v. usual care.
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effective in comparison with usual care is 79.2% for a
willingness-to-pay threshold of e20,000 per additional
QALY, increasing to a probability above 98.5% and
higher for thresholds of e50,000 and higher (Figure 4).
Validation results
Life expectancy predicted by the model varied from 33.7
to 36.1 years for the different DMD options and best
supportive care. Considering a mean age of treatment
start at 37 years, a life expectancy of 83.3 years for the
general Dutch population,76 and a reduced life expec-
tancy of 7 to 14 years for MS patients,77 the life expec-
tancy estimated by the model (70.7 to 73.1 years)
corresponds thus with published estimates.
Discussion
Using a state transition model, this study suggests that
shared decision making for DMDs for RRMS has the
potential to be cost-effective, from a limited societal Dutch
perspective, in comparison with usual care. Assuming that
shared decision making would reduce discontinuation rates
by 50%, increase the proportion of adherent patients by
5%, and lead to a slight increase in DMD initiation and
the uptake of second-line and orally administered first-line
DMDs, the ICER fell below accepted cost-effectiveness
thresholds of e50,000 for diseases categorized as moder-
ately burdensome in the Netherlands.74 The probability
that the intervention would be cost-effective in compari-
son with usual care was 98.5% for a threshold of e50,000
per QALY. One-way sensitivity analyses showed that the
ICER was robust for changes in costs of the intervention
but more sensitive to variation in relative risk of progres-
sion for each DMD, drug costs, discount rates, or changes
in perspectives. Nonetheless, all ICERs in the sensitivity
analyses remained well below the commonly accepted
threshold for cost-effectiveness of e50,000 per QALY
gained,74 except when the relative risk of progression for
each DMD would be considerably higher.
Threshold analyses showed that shared decision mak-
ing will be cost-effective up to a maximum cost of
e23,639 for a threshold of e50,000 per QALY, assuming
the intervention would result in changes in initial treat-
ment choice and a decrease in the discontinuation rate
and the proportion of nonadherent patients. This maxi-
mum cost is very unlikely to be reached, as increase in
consultation time would cost e104 per additional consul-
tation, and training of health care professionals, develop-
ment, and delivery of patient decision aids would in the
worst-case scenario never add up to e23,639.
Two similar exploratory studies regarding the cost-
effectiveness of shared decision making have been con-
ducted, for obstructive sleep apnea and osteoporosis, and
concluded that a patient decision aid could potentially be
cost-effective.42,43 In contrast to our study, these studies
found that the intervention’s cost of delivery had substan-
tial influence on the cost-effectiveness of a patient decision
aid, in addition to the influence of variations in the cost of
the treatment.43 We found that the cost of shared decision
making had little impact on the ICER. This could be
explained by the considerable difference in treatment costs
for obstructive sleep apnea and osteoporosis, which were
only a fraction of the treatment costs for RRMS.
The actual effects of shared decision making for RRMS
on treatment choice, persistence, adherence, and the
cost of implementing the intervention are still largely
unknown. Therefore, our study has an exploratory
nature. Further trial- and registry-based evaluations
would be needed to assess the real-life effects of shared
decision making for MS. Modeling each potential
effect of shared decision making separately allowed for
assessment as to which of the 3 expected effects were
most influential with regard to its cost-effectiveness
and therefore informs further research and develop-
ment of the intervention. Improvement in treatment
adherence was found to have little effect on total
QALYs. Various studies on enhancing adherence to
medical intervention also failed to find a QALY and/or
cost improvement with increased adherence rates—
larger than the assumed adherence rate in our study—
in trial-based economic evaluations.78,79 In contrast,
the other 2 effects did affect the cost-effectiveness: a
change in treatment initiation resulted in more incre-
mental QALYs gained, and decreased discontinuation
rates brought about the largest incremental QALY
gain. If shared decision making would reduce the dis-
continuation by only 25%, increased drug costs are
leveled out by reduced health state costs, causing
shared decision making to be dominant over usual
care, while with higher relative reductions in disconti-
nuation rate, the drug cost increase exceeds the savings
in health state costs. The importance of using shared
decision making in decreasing discontinuation was also
found for patient decision aids, which support shared
decision making in osteoporosis.42 Our results suggest
that the development of interventions to support
shared decision making for RRMS should focus mainly
on reducing the discontinuation of DMDs for the inter-
ventions to be cost-effective, since the type of treatment
initiated is dependent on the patient’s preferences and
needs and should not be directed by any intervention.
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A strength of the current study is that a previously
developed and validated model, used by regulatory bod-
ies for policy decision making and pricing, was adapted
to explore the cost-effectiveness of shared decision mak-
ing in comparison with usual care. Moreover, a number
of sensitivity analyses were conducted to establish the
robustness of the results and conclusions. Inherent to the
study design, however, is the simplification of real-life
situations in a model. In addition to the limitations
described by Zimmerman et al.40 concerning the quality
and quantity of data available for the natural history of
MS and DMD effectiveness, this model has some addi-
tional limitations. First, the model is based on the
assumption that once patients choose best supportive
care, as first, second, or third treatment course, they
remain on best supportive care. In clinical practice, how-
ever, patients might choose to postpone treatment ini-
tially but decide after a while to start a DMD. This
might underestimate the increase in drug costs as a con-
sequence of shared decision making in comparison with
usual care and thus, to some extent, the ICER. Further
research is needed on whether shared decision making
affects the probability of patients starting DMDs after
initially opting for best supportive care. Second, nonad-
herence might increase over time, while in the model,
nonadherence is assumed to be constant over time. This
could overestimate the effect of shared decision making.
Third, the mean age of RRMS onset, and thus the mean
age of patients entering the model, might actually be
lower. The estimate was based on cost-of-illness studies
in the Netherlands, including patients who self-reported
their disease course as RRMS, SPMS, and PPMS or
don’t know. Patients may experience difficulty in identi-
fying their disease course,80 and PPMS patients have on
average a higher age of disease onset than RRMS and
SPMS patients.81 Although a number of model-based
economic evaluations included populations with similar
mean ages at onset based on study samples from pivotal
DMD studies, ranging from 36 to 38 years,29,32,82–85
some other studies included populations with mean ages
of 2940 or 3332 years. Sensitivity analyses show that with
lower ages of mean onset, shared decision making
becomes more cost-effective, reducing the ICER with
17% (e3064) per QALY in comparison with the base
case analysis. Fourth, cladribine has currently become
available for patients with highly active RRMS or for
patients who did not respond to a first-line DMD11 but
was not included in the model as treatment option. Since
cladribine received market authorization for highly
active RRMS only in 2017 and was not included in the
basic health insurance package in the Netherlands until
March 2018, we expect that the share of patients cur-
rently choosing cladribine would be small and therefore
have only a marginal impact on the results.
This exploratory study was specifically conducted for
the Netherlands. Certain aspects of our model may limit
the applicability of the results to contexts other than the
Netherlands. For example, drug costs and recommenda-
tions for treatment sequencing (including the categorization
in first-line and second-line therapy) differ between coun-
tries. In sensitivity analyses, we increased the drug cost of
all DMDs by 20%, which showed that this parameter has a
substantial effect on the ICER. In this scenario, the Dutch
drug costs would still be 50% to 84% lower than the US
drug costs.40 Shared decision making may, therefore, have
more substantial impact on drug costs and the ICER in the
United States. Moreover, assumed treatment sequencing
was validated with Dutch clinicians, but clinical practice
could differ in other countries86: for example, fingolimod is
prescribed in the Netherlands only after another DMD has
been ineffective but is approved as a first-line treatment
option in the United States.
In conclusion, this study suggests that shared decision
making for RRMS could potentially be a cost-effective
intervention. Although shared decision making requires
short-term investments in training staff, setting up struc-
tures for shared decision making and developing and/or
acquiring patient decision aids, long-term savings should
be considered in policy decisions, since threshold analyses
show that shared decision making could be cost-effective
even if upfront intervention cost are high. To our knowl-
edge, this is the first study assessing the potential cost-
effectiveness of shared decision making for RRMS. The
current study could further inform the design of a trial-
based study, which should be conducted to verify the
assumptions made in the study and its results. This study
provides insights for policy makers and clinicians regarding
the potential value of implementing appropriate interven-
tions to support shared decision making in treatment deci-
sions for RRMS. Real-world current evidence on the cost-
effectiveness of shared decision making is still limited23 and
not available for RRMS. Real-world data on long-term
treatment discontinuation rates after shared decision mak-
ing should be collected.
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